Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity

Journal of the Formosan Medical Association

Volumn 114, Issue 7, 2015, Pages 583-589

  Chen, Sheng Fu ^a   Kuo, Hann Chorng ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Botulinum toxin A; Incontinence; Neurogenic detrusor; Overactivity; Spinal cord injury

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; AUTONOMIC DYSREFLEXIA; BLADDER RECONSTRUCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DETRUSOR MUSCLE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; NEUROGENIC BLADDER; PATIENT SATISFACTION; RECURRENT INFECTION; SPINAL CORD INJURY; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; URODYNAMICS; UROGENITAL DISTRESS INVENTORY 6; UROLOGIC EXAMINATION; AGED; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; INJECTION; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; CHRONIC DISEASE; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SPINAL CORD INJURIES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URODYNAMICS; YOUNG ADULT;

EID: 84937251438     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.10.009     Document Type: Article

References (20)

1. Sekhon L.H., Fehlings M.G. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 2001, 26(24 Suppl.):S2-12.
2. Patki P.S., Hamid R., Arumugam K., Shah P.J., Craggs M. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 2006, 98:77-82.
3. Stohrer M., Blok B., Castro-Diaz D., Chartier-Kastler E., Del Popolo G., Kramer G., et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009, 56:81-88.
4. Razdan S., Leboeuf L., Meinbach D.S., Weinstein D., Gousse A.E. Current practice patterns in the urologic surveillance and management of patients with spinal cord injury. Urology 2003, 61:893-896.
5. Andersson K.E. Antimuscarinics for treatment of overactive bladder. Lancet Neurology 2004, 3:46-53.
6. Schurch B., Stohrer M., Kramer G., Schmid D.M., Gaul G., Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164:692-697.
7. Kalsi V., Apostolidis A., Popat R., Gonzales G., Fowler C.J., Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006, 49:528-535.
8. Cruz F., Herschorn S., Aliotta P., Brin M., Thompson C., Lam W., et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011, 60:742-750.
9. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167-178.
10. Waring W.P., Biering-Sorensen F., Burns S., Donovan W., Graves D., Jha A., et al. 2009 review and revisions of the international standards for the neurological classification of spinal cord injury. J Spinal Cord Med 2010, 33:346-352.
11. Mangera A., Andersson K.E., Apostolidis A., Chapple C., Dasgupta P., Giannantoni A., et al. Contemporary management of lower urinary tract disease with botulinum toxin A: A systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011, 60:784-795.
12. Reitz A., Stohrer M., Kramer G., Del Popolo G., Chartier-Kastler E., Pannek J., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004, 45:510-515.
13. Schurch B., de Sèze M., Denys P., Chartier-Kastler E., Haab F., Everaert K., et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005, 174:196-200.
14. Kuo H.C. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004, 63:868-872.
15. Ginsberg D., Gousse A., Keppenne V., Sievert K.D., Thompson C., Lam W., et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012, 187:2131-2139.
16. Sussman D., Patel V., Del Popolo G., Lam W., Globe D., Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn 2013, 32:242-249.
17. Kuo H.C., Liu S.H. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. Neurourol Urodyn 2011, 30:1541-1545.
18. Haferkamp A., Schurch B., Reitz A., Krengel U., Grosse J., Kramer G., et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004, 46:784-791.
19. Grosse J., Kramer G., Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005, 47:653-659.
20. Mohee A., Khan A., Harris N., Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013, 111:106-113.